Effects of Intravitreal Bevacizumab (Avastin®) Therapy on Retrobulbar Blood Flow Parameters in Patients With Neovascular Age-Related Macular Degeneration

被引:24
|
作者
Mete, Ahmet [1 ]
Saygili, Oguzhan [2 ]
Mete, Alper [2 ]
Bayram, Metin [1 ]
Bekir, Necdet [2 ]
机构
[1] Gaziantep Univ, Sch Med, Dept Radiol, Sahinbey, Gaziantep, Turkey
[2] Gaziantep Univ, Sch Med, Dept Ophtalmol, Sahinbey, Gaziantep, Turkey
关键词
color Doppler imaging; retrobulbar blood flow; neovascular age-related macular degeneration; intravitreal bevacizumab injection; ENDOTHELIAL GROWTH-FACTOR; DOPPLER ULTRASONOGRAPHY; HEMODYNAMICS; ORBIT; EYE; MACULOPATHY; SAFETY; EDEMA;
D O I
10.1002/jcu.20650
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Background. To investigate the effects of intravitreal bevacizumab on retrobulbar circulation in patients with neovascular age-related macular degeneration (AMD). Method. Thirty patients with neovascular age-related macular degeneration were assessed prospectively by both color Doppler imaging and fundus fluorescein angiography. Spectral Doppler analysis allowed the measurement of the maximum velocity (Vmax) and minimum velocity (Vmin) of the central retinal vein (CRV), and peak systolic (PSV), end-diastolic (EDV) velocities of blood flows, and pulsatility index (PI) and resistance index (RI) values in the central retinal artery (CRA), nasal and temporal posterior ciliary arteries (NPCA, TPCA), and ophthalmic artery (OA). The t test for paired samples was used to compare retrobulbar blood flow values before and after intravitreal bevacizumab injection. Result. PSV and EDV of the NPCA and PSV of the TPCA were significantly decreased after intravitreal bevacizumab injection (p < 0.05). There was no statistically significant difference in the other parameters. Conclusion. Our results suggest that intravitreal bevacizumab therapy has a measurable effect on retrobulbar blood flow. (C) 2009 Wiley Periodicals, Inc. J Clin Ultrasound 38:66-70, 2010; Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jcu.20650
引用
收藏
页码:66 / 70
页数:5
相关论文
共 50 条
  • [21] Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study
    Maura Lucy Abrahám-Marin
    Carlos Fernando Cortés-Luna
    Griselda Álvarez-Rivera
    Myriam Hernández-Rojas
    Hugo Quiroz-Mercado
    Virgilio Morales-Cantón
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245 : 651 - 655
  • [22] The effect of intravitreal bevacizumab (Avastin (R)) on ocular pulse amplitude in neovascular age-related macular degeneration
    Rechtman, Ehud
    Stalmans, Ingeborg
    Glovinsky, Joseph
    Breusegem, Christophe
    Moisseiev, Joseph
    Van Calster, Joachim
    Harris, Alon
    CLINICAL OPHTHALMOLOGY, 2011, 5 : 37 - 44
  • [23] A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
    Arias, L.
    Caminal, J. M.
    Casas, L.
    Masuet, C.
    Badia, M. B.
    Rubio, M.
    Pujol, O.
    Arruga, J.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (12) : 1636 - 1641
  • [24] Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration
    Karanjia, R.
    Eng, K. T.
    Gale, J.
    Sharma, S.
    ten Hove, M. W.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (09) : 1248 - 1252
  • [25] Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage
    Stifter, Eva
    Michels, Stephan
    Prager, Franz
    Georgopoulos, Michael
    Polak, Kaija
    Hirn, Cornelia
    Schmidt-Erfurth, Ursula
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 144 (06) : 886 - 892
  • [26] Intravitreal bevacizumab vs verteporfin photodynamic therapy for Neovascular age-related macular degeneration
    Bashshur, Ziad F.
    Schakal, Alexandre
    Hamam, Rola N.
    El Haibi, Christelle P.
    Jaafar, Rola F.
    Noureddin, Baha' N.
    ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (10) : 1357 - 1361
  • [27] Verteporfin Photodynamic Therapy Combined With Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration
    Kaiser, Peter K.
    OPHTHALMOLOGY, 2009, 116 (04) : 747 - 755
  • [28] Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature
    S Jyothi
    H Chowdhury
    M Elagouz
    S Sivaprasad
    Eye, 2010, 24 : 816 - 824
  • [29] Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration
    Landa, Gennady
    Amde, Wendewessen
    Doshi, Vatsal
    Ali, Amro
    McGevna, Laura
    Gentile, Ronald C.
    Muldoon, Thomas O.
    Walsh, Joseph B.
    Rosen, Richard B.
    OPHTHALMOLOGICA, 2009, 223 (06) : 370 - 375
  • [30] Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration
    Rosenfeld, PJ
    Moshfeghi, AA
    Puliafito, CA
    OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04): : 331 - 335